非酒精性脂肪性肝病与肝细胞癌发生

doi:10.3969/j.issn.1672-5069.2016.01.033

Abstract

Abstract: Incidence of hepatocellular carcinoma（HCC） is increasing worldwide. The development of HCC tends to be related to hepatitis virus infection. However,nonalcoholic fatty liver disease is another important cause of hepatocellular carcinoma. In recent years,with the change of lifestyle and diet habits,the incidence of nonalcoholic fatty liver disease is increasing,and more and more studies have focus on the relationship between nonalcoholic fatty liver disease and hepatocellular carcinoma. The process,risk factors and mechanism of nonalcoholic fatty liver disease–related hepatocellular carcinoma will be reviewed in this paper.

Key words: Hepatocellular carcinoma, Nonalcoholic fatty liver diseases, Mechanism

Liang Qianfei, Zhao Caiyan. Hepatocellular carcinoma in patients with nonalcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 113-116.

References

[1] Ferlay J,Soerjomataram I,Dikshit R,et al. Cancer incidence and mortality worldwide：sources,methods and major patterns in GLOBOCAN 2012. Int J Cancer,2015,136（5）：E359–E386.
[2] Fan JG,Farrell GC. Epidemiology of non–alcoholic fatty liver disease in China. J Hepatol,2009,50（1）：204–210.
[3] Kikuchi L,Oliveira CP,Carrilho FJ. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Biomed Res Int,2014,10（62）：4-7.
[4] Farrell GC,Larter CZ. Nonalcoholic fatty liver disease：from steatosis to cirrhosis. Hepatology,2006,43（2 Suppl 1）：S99–S112.
[5] de Alwis NM,Day CP. Non–alcoholicfattyliverdisease：the mistgraduallyclears. J Hepatol,2008,48 （Suppl 1）：S104–S112.
[6] Ascha MS,Hanouneh IA,Lopez R,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology,2010,51（6）：1972–1978.
[7] Adams LA,Lymp JF,St Sauver J,et al. The natural history of nonalcoholic fatty liver disease：a population–basedcohort study. Gastroenterology,2005,129（1）：113–121.
[8] Nascimbeni F,Pais R,Bellentani S,et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol,2013,59（4）：859–871.
[9] Chagas AL,Kikuchi LO,Oliveira CP,et al. Does hepatocellular carcinoma in non–alcoholic steatohepatitis exist in cirrhotic and non–cirrhotic patients? Braz J Med Biol Res,2009,42（10）：958–962.
[10] Hashimoto E,Yatsuji S,Tobari M,et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol,2009,44 （Suppl 19）：89–95.
[11] Marrero JA,Fontana RJ,Su GL,et al. NAFLD may be a commonunderlyingliver disease in patients with hepatocellular carcinoma in the United States. Hepatology,2002,36（6）：1349–1354.
[12] Caldwell SH,Oelsner DH,Iezzoni JC,et al. Cryptogenic cirrhosis：clinical characterization and risk factors for underlying disease. Hepatology,1999,29（3）：664–669.
[13] Bugianesi E,Leone N,Vanni E,et al. Expanding the natural history of nonalcoholic steatohepatitis：from cryptogeniccirrhosis to hepatocellular carcinoma. Gastroenterology,2002,123（1）：134–140.
[14] Hashizume H,Sato K,Takagi H,et al. Primary liver cancers with nonalcoholic steatohepatitis.Eur J Gastroenterol Hepatol,2007,19（10）：827–834.
[15] Hui JM,Kench JG,Chitturi S,et al. Long–termoutcomes of cirrhosis in nonalcoholic steatohepatitiscompared with hepatitis C. Hepatology,2003,38（2）：420–427.
[16] Moller H,Mellemgaard A,Lindvig K,et al. Obesity and cancerrisk：a Danishrecord–linkage study. Eur J Cancer,1994,30A（3）：344–350.
[17] Larsson SC,Wolk A. Overweight,obesity and risk of liver cancer：a meta–analysis of cohort studies.Br J Cancer,2007,97（7）：1005–1008.
[18] Jee SH,Yun JE,Park EJ,et al. Body mass index and cancer risk in Korean men and women. Int J Cancer,2008,123（8）：1892–1896.
[19] Calle EE,Rodriguez C,Walker–Thurmond K,et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med,2003,348（17）：1625–1638.
[20] Lai SW,Chen PC,Liao KF,et al. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti–diabetic therapy：a population–based cohort study. Am J Gastroenterol,2012,107（1）：46–52.
[21] Campbell PT,Newton CC,Patel AV,et al. Diabetes and cause–specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care,2012,35（9）：1835–1844.
[22] Ikeda Y,Shimada M,Hasegawa H,et al. Prognosis of hepatocellular carcinoma with diabetes mellitusafterhepaticresection.Hepatology,1998,27（6）：1567–1571.
[23] Masood MA,Zafar W, Yusuf MA. Is diabetes mellitus a poor prognostic factor for hepatocellular carcinoma? J Gastrointest Cancer,2014,45（4）：448–451.
[24] Sorrentino P, D’Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non–alcoholic steatohepatitis.See comment in PubMed Commons belowJ Hepatol,2009,50（2）：351–357.
[25] Vinciguerra M,Carrozzino F,Peyrou M,et al. Unsaturated fatty acids promote hepatoma proliferation and progression through down regulation of the tumor suppressor PTEN.J Hepatol,2009,50（6）：1132–1141.
[26] Kimura O,Kondo Y,Shimosegawa T. PPAR could contribute to the pathogenesis of hepatocellular carcinoma. PPAR Res,2012,2012（5）：74-80.
[27] Page JM,Harrison SA. NASH and HCC. Clin Liver Dis,2009,13（4）：631–647.
[28] Stojsavljevic S,Gomercic Palci M,Virovic Jukic L,et al. Adipokines and proinflammatory cytokines,the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol,2014,20（48）：18070–18091.
[29] Chen C,Chang YC,Liu CL,et al. Leptin induces proliferation and anti–apoptosis in human hepatocarcinoma cells by up–regulating cyclin D1 and down–regulating Bax via a Janus kinase 2–linked pathway. Endocr Relat Cancer,2007,14（2）：513–529.
[30] Stefanou N,Papanikolaou V,Furukawa Y,et al. Leptin as a critical regulator of hepatocellular carcinoma development through modulation of human telomerase reverse transcriptase. BMC Cancer,2010,10：442.
[31] Saxena NK,Fu PP,Nagalingam A,et al. Adiponectin modulates C–jun N–terminal kinase and mammalian target of rapamycin and inhibits hepatocellular carcinoma. Gastroenterology,2010,139（5）：1762–1773.
[32] Sharma D,Wang J,Fu PP,et al. Adiponectin antagonizes the oncogenicactions of leptin in hepatocellular carcinogenesis. Hepatology,2010,52（5）：1713–1722.
[33] 赵彩彦,孔令波,李亚,等. 非酒精性脂肪性肝病患者肝组织脂联素表达及其意义. 中国肝脏病杂志（电子版）,2009,1（2）：4–8.
[34] Sasaki Y. Does oxidative stress participate in the development of hepatocellular carcinoma. J Gastroenterol,2006,41（12）：1135–1148.
[35] Xu Z,Chen L,Leung L,et al. Liver–specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci U S A,2005,102（11）：4120–4125.
[36] Wu Y,Zhou BP. TNF–alpha/NF–kappa B/Snail pathway in cancer cell migration and invasion. Br J Cancer,2010,102（4）：639–644.
[37] Alzahrani B,Iseli TJ,Hebbard LW. Non–viral causes of liver cancer： does obesity led inflammation play a role? Cancer Lett,2014,345（2）：223–229.
[38] Jiao M,Ren F,Zhou L,et al. Peroxisome proliferator–activated receptor α activation attenuates the inflammatory response to protect the liver from acute failure by promoting the autophagy pathway. Cell Death Dis,2014,5：e1397.
[39] Petrovski G,Zahuczky G,Májai G,et al. Phagocytosis of cells dying through autophagy evokes a pro–inflammatory response in macrophages.Autophagy,2007,3（5）：509–511.
[40] Tian Y,Kuo C,Sir D,et al. Autophagy inhibits oxidative stress and tumor suppressors to exert its dual effect on hepatocarcinogenesis. Cell Death Differ,2014：201.

Hepatocellular carcinoma in patients with nonalcoholic fatty liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Pan Meimin, Li Wenjuan, Jiang Fangqing, et al.. Changes of serum IL-17A,fibroblast growth factor and IL-7 levels in patients with hepatitis C virus infection [J]. Journal of Practical Hepatology, 2019, 22(6): 840-843.
[2]	Cao Ce, Yu Yixing, Wang Beibei, et al.. Clinical diagnostic efficacy of enhanced magnetic resonance imaging combined with serum AFP and PIVKA-Ⅱ in the diagnosis of patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 896-899.
[3]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[4]	Xing Hao, Han Jun, Yang Tian.. Diagnostic value of serum protein induced by vitamin K absence or antagonist II for hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2019, 22(6): 934-937.
[5]	Zhu Jun, Ding Ying, Wang Shiqing, et al. Peripheral blood Th22 cells and plasma interleukin-22 level changes in patients with hepatocellular carcinoma after hepatectomy and administration of ulinastatin [J]. Journal of Practical Hepatology, 2019, 22(5): 720-723.
[6]	Wang Gang, Zhao Hongbo, Zhu Yaling, et al. Cancerous XPO5 gene level in patients with hepatocellular carcinoma and its clinical significance [J]. Journal of Practical Hepatology, 2019, 22(5): 724-727.
[7]	Xiao Han, Wang Li. Mechanisms of thrombocytopenia in liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 462-465.
[8]	Qiao Zhizhong. Value of contrast-enhanced ultrasonography in differential diagnosis of patients with focal nodular hyperplasia and hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 421-424.
[9]	Zhu Guangxi，Wen Liangzhi，Chen Dongfeng. Pathogenesis of non-alcoholic fatty liver disease-related hepatocellular carcinoma [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 453-456.
[10]	Wang Huming, Fan Dongsheng, Xu Jie, Liu Xianfegn, Zhou Ning, Li Min, Bao Nana. Cancerous miRNA-30c levels affecting the survival of patients with hepatocellular carcinoma after hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 248-251.
[11]	Xing Diankui, Cheng Jing. Clinical value of ¹⁸F-FDG PET/CT scan in patients with hepatocellular carcinoma and hepatic microvascular invasion [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 252-254.
[12]	Wang Xiuqing, Ma Yanjun, Zhan Jinli. Efficacy of transcatheter arterial chemoembolization and ultrasound-guided microwave ablation in the treatment of patients with hepatocellular carcinoma at special sites [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 260-263.
[13]	Zhang Xiaozhou, Shuai Ling, Wang Qingda, Yang Nan. Changes of serum miR-335 levels in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 268-271.
[14]	Wang Zhaoxia, Guan Ke, Fu Sanxian, Wang Huijie. Early administration of enteral nutrition in patients with hepatocellular carcinoma undergoing hepatectomy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 272-275.
[15]	Zhao Xitai, Nie Qinghe. Serum microRNA in diagnosis of patients with hepatocellular carcinoma and methodological progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 297-300.